Latest Healthcare It News

CLINUVEL Pharmaceuticals has completed recruitment for its Phase III trial of SCENESSE® in vitiligo patients with darker skin types, setting the stage for first results in late 2026. Early clinical observations suggest promising repigmentation outcomes.

MedAdvisor Limited has received a non-binding offer from a major multinational software company to acquire its ANZ business division, valuing it above current market expectations.

SPC Global Holdings confirms FY2025 pro forma EBITDA guidance of A$29 million, driven by strong early post-merger performance and strategic initiatives including site consolidation and leadership renewal.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

EZZ Life Science Holdings Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the six months ending December 2024, signaling steady returns for shareholders.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Sigma Healthcare’s recent merger with Chemist Warehouse Group is delivering strong earnings growth, with Normalised EBIT rising 36% in the first half of FY25. Transaction costs remain significant but the combined group’s outlook appears robust.

Beamtree Holdings has landed a landmark NHS contract and multiple international deals, positioning itself for robust annual recurring revenue growth and improved profitability by the end of FY25.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.

Healius Limited has announced a special fully franked dividend of AUD 0.413 per ordinary share, signaling confidence in its financial position despite the ongoing suspension of its Dividend Reinvestment Plan.